Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours (CLARINET)
Endocrine Tumors
About this trial
This is an interventional treatment trial for Endocrine Tumors focused on measuring Non functioning entero-pancreatic tumours
Eligibility Criteria
Inclusion Criteria: Endocrine tumour in the intestine or pancreas and with locally advanced or metastatic disease No hormone related symptoms Well or moderately differentiated tumour confirmed by histology Tumour lesions which are measurable by a CT or MRI scan Exclusion Criteria: Previously treated with a somatostatin analogue unless more than 6 months ago and given for no more than 15 days Treated within the last 6 months with interferon, chemoembolisation or chemotherapy or at any time with a radionuclide Had a previous cancer except basal cell carcinoma and/or in situ carcinoma of the cervix/uterus and/or patients treated with curative intent and free from disease for 5 years Pregnant or lactating Females must use adequate contraception during the study
Sites / Locations
- Cedars-Sinai Outpatient Cancer Center
- University of Iowa
- The John Hopkins Hospital
- Dana Farber Cancer Institute
- Memorial Sloan-Kettering Cancer Center
- Providence Portland Medical Center
- MD Anderson Cancer Center
- University of Wisconsin School of Medicine and Public Health
- University Hospital
- UZ Antwerpen
- UCL Saint Luc
- UZ Gent
- Fakultni nemocnice Na
- Fekultni nemocnice Olomouc
- General faculty
- Sygehus Hospital
- Rigshospitalet
- Hôpital A. Paré
- Hôpital Beaujon
- CAC Oscar Lambret
- Hôpital Edouard Herriot
- CHU la Timone
- Hôpital R. Debré
- CHI Frejus St Raphael
- Hôpital Rangueil
- Unité de gastro enterologie IGR
- Charite Hospital
- University Hospital
- University Hospital
- Gutenberg University Hospital
- University Hospital
- Lukas Hospital
- Global Hospital
- Tata Memorial Hospital
- Centro di Refierimiento Oncologica
- Azienda Malpighi
- INSCT
- University of Naples
- Hospital S. Chiara
- Azienda San Giovanni Battista
- UMC Gronigen
- Erasmu MC
- UMC Utrecht
- Centrum Onkologii-Instytut im. Marii Sklodowskiej - Curie, oddzial w Gliwicach, Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej ul.
- Katedra i Klinika Endokrynologii Przemiany Materii i Chorob Wewnetrznych Uniwersytetu Medycznego w Poznaniu
- Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika Chorob Wewnetrznych I Endokrynologii ul. Banacha 1 a
- Szpital Bielanski im. Ks. Jerzego Popieluszki, Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Klinika Endokrynologii Centrum Medycznego Ksztalcenia Podyplomowego
- Zaklad Diagnosttyki Radiologicznej, Centralny Szpital Klincny, Ministrerstwa Spraw Wewnetrznych i Administratracji w Warzawie
- Silesian Medical University
- Narodny onkologicky ustav, Bratislava
- Vychodoslovensky onkologicky ustav, Rastislavova
- Hospital Vall d'Hebron
- Institut Catala Oncologia
- Hospital G. Maranon
- Hospital La Paz
- Hospital Nuestra Senora de la Candelaria
- Sahlgrenska Hospital
- Karolinska University Hospital
- University Hospital
- Basingstoke and North Hampshire Hospital
- Royal Victoria Hospital
- University Hospital Wales
- Western General Hospital
- Beatson West of Scotland Cancer Centre
- St James Hospital
- Leicester Royal Infirmary
- Royal Free Hospital
- St Bartholomew's Hospital
- QMC
- Churchill Hospital
- Royal Hallamshire Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
lanreotide (Autogel formulation)
Placebo